In conclusion, in this HRQoL analysis of previously treated patients with EGFR ex20ins+ mNSCLC, the first such analysis for an oral exon 20–targeted therapy, PRO results with mobocertinib treatment showed improvements in core lung cancer symptoms and maintenance of overall HRQoL and functions, despite AEs, such as diarrhea, dry skin, rash, and decreased appetite. This evidence concerns the gene EGFR and lung carcinoma.